Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.

ABSTRACT:

Background

Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which contribute to disease progression, is important to guide preventative treatment and improve outcomes. Blood eosinophils are a biomarker for patient responsiveness to inhaled corticosteroids (ICS); however, their effectiveness as a predictive biomarker for COPD exacerbations is unclear.

Methods

This post hoc analysis pooled data from 11 Boehringer Ingelheim-sponsored Phase III and IV randomised COPD studies with similar methodologies. Exacerbation data were collected from these studies, excluding patients from the ICS withdrawal arm of the WISDOM® study. Patients were grouped according to their baseline bl

SUBMITTER: Singh D 

PROVIDER: S-EPMC7499955 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature